Bio-Techne to Present its Portfolio Manufacturing Cell and Gene Therapy Tools at Phacilitate Advanced Therapies Week 2024
9 January 2024
Bio-Techne Corporation, Bio-Techne, has confirmed that it will showcase its product portfolio and solutions to enable cell and gene therapy development and manufacturing at Advanced Therapies Week 2024, featuring its wide range of products, services and capabilities to demonstrate the enablement of cell and gene therapy development and workflow solutions.
Bio-Techne has confirmed attendance at Advanced Therapies Week 2024, January 16-19, and will be at booth #509, featuring its wide range of products, services and capabilities to demonstrate the enablement of cell and gene therapy development and workflow solutions.
Particularly, on Friday, January 19 at 10:00 AM EST David Hermanson, Director for Cell & Gene Therapy Applications at Bio-Techne, will present a technical talk on the non-viral gene editing TcBuster™ transposon system. The technical talk will focus on how gene-modified cell therapies can be manufactured at scale using the TcBuster transposon system, specialty media, and liquid cytokines in the G-Rex® bioreactor.
“My presentation will be a wonderful opportunity for attendees to learn how immune cell therapy development programs can benefit from a streamlined T cell manufacturing workflow and licensable transposon system for non-viral gene engineering,” highlighted Dr. Hermanson.
Dr. Hermanson’s talk will also describe how automated Simple Plex™ immunoassays on Ella™ can be used for the functional assessment of CART cells.
There will also be hosting a roundtable discussion bringing together industry leaders to discuss the importance of scalable and cost-effective closed-system solutions for CAR-T cell manufacturing featuring ScaleReady, Bio-Techne’s strategic partnership with Fresenius Kabi and Wilson Wolf for integrated immune cell therapy manufacturing workflow solutions.
“In partnership with ScaleReady, Bio-Techne is proud to offer flexible cell and gene therapy workflow solutions that simplify the transition from RUO to GMP and allow for seamless process scale-up, enabling our customers to get their therapies to the clinic with speed and consistency,” said Will Geist, President of Bio-Techne’s Protein Sciences Segment.
Technical Talk with David Hermanson, PhD as Presenter, Friday, January 19th at 10:00 AM EST, Theatre 2
Non-Viral Manufacturing of Gene Modified CAR T Therapies Using TcBuster™
Presentation: Non-Viral Solutions for Gene Therapy
Roundtable Talk, Thursday, January 18th, at 8:00 AM EST, Theatre 2
Cell Therapy Manufacturing: A Look Under the Hood – Learning from Outside the Industry. Can we make CAR-T cells like we make cars?
Josh Ludwig, Global Commercial Director ScaleReady – Moderator
Ignacio Nunez, Founder and CEO BioExcellence LLC – Presenter and panelist
Ricardo Jimenez, SVP Tech Ops at Neurogene – Panelist Sarah Madonna, Sr Dir Manufacturing at Kiromic Biopharma – Panelist
Nick Casale, VP Global Facilities & Corporate Engineering Ultragenyx Pharmaceutical– Panelist About Bio-Techne
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.